Immunization with a double-mutant (R192G/L211A) of the heat-labile enterotoxin of Escherichia coli offers partial protection against campylobacter jejuni in an adult mouse intestinal colonization model

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Albert, M John ^a   Haridas, Shilpa ^a   Ebenezer, Mathew ^a   Raghupathy, Raj ^a   Khan, Islam ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROTOXIN; HEAT LABILE ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; MAJOR OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; TOXIN ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL TOXIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; ESCHERICHIA COLI PROTEIN; IMMUNOLOGICAL ADJUVANT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL COLONIZATION; CAMPYLOBACTER ENTERITIS; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; CROSS REACTION; ENTEROTOXIGENIC ESCHERICHIA COLI; IMMUNITY; IMMUNIZATION; MOUSE; MUTANT; NONHUMAN; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; FECES; HEAT; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; CAMPYLOBACTER JEJUNI; DISEASE MODELS, ANIMAL; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FECES; HOT TEMPERATURE; IMMUNIZATION; INTESTINES; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 84951299506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142090     Document Type: Article

References (45)

1. Newell DG, Koopmans M, Verhoef L, Duizer E, Aidara-Kane A, Sprong H, et al. Food-borne diseases-The challenge of 20 years ago still persists while new ones continue to emerge. Int J Food Microbiol. 2010; 139 (Suppl): S3-S15.
2. Friedman CR, Neimann J, Wegener HC, Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In Nachamkin I, Blaser MJ, editors. Campylobacter, 2nd ed. Washington, DC: American Society for Microbiology; 2000. pp. 121-38.
3. Oberhelman RA, Taylor DN. Campylobacter infections in developing countries. In Nachamkin I, Blaser MJ, editors. Campylobacter, 2nd ed. Washington, DC: American Society for Microbiology; 2000. pp. 139-54.
4. Blaser MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis. 1997; 176 (Suppl 2): S103-S5. PMID: 9396691
5. Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-Associated Guillain-Barre? syndrome. J Infect Dis. 1997; 176 (Suppl 2): S192-S7. PMID: 9396710
6. Scott DA. Vaccines against Campylobacter jejuni. J. Infect. Dis. 1997; 176 (Suppl 2): S183-S8. PMID: 9396708
7. World Health Organization. State of the art of vaccine research and development. 2006. WHO/IVB/06.1. Available: www.who.int/vaccines-documents/
8. Albert MJ. Vaccines against Campylobacter jejuni. Austin J Clin Immunol. 2014; 1(3): 1013.
9. Albert MJ, Haridas S, Steer D, Dhaunsi GS, Smith AI, Adler B. Identification of a Campylobacter jejuni protein that cross-reacts with cholera toxin. Infect Immun. 2007; 75: 3070-3. PMID: 17438040
10. Albert MJ, Haridas S, Adler B. Major outer membrane proteins from many Campylobacter species cross-react with cholera toxin. Clin Vaccine Immunol. 2008; 15: 859-62. doi: 10.1128/CVI.00471-07 PMID: 18353926
11. Albert MJ, Mustafa AS, Islam A, Haridas S. Oral immunization with cholera toxin provides protection against Campylobacter jejuni in an adult mouse intestinal colonization model. 2013; mBio 4: e00246-13 doi: 10.1128/mBio.00246-13 PMID: 23653448
12. Holmner A, Mackenzie A, Okvist M, Jansson L, Lebens M, Teneberg S, et al. Crystal structures exploring the origins of the broader specificity of Escherichia coli heat-labile enterotoxin compared to cholera toxin. J Mol Biol. 2011; 406: 387-402. doi: 10.1016/j.jmb.2010.11.060 PMID: 21168418
13. Katz JM, Lu X, Young SA, Galphin JC. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis.1997; 175: 352-63. PMID: 9203656
14. Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, et al. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine. 1995; 13: 22-8. PMID: 7539199
15. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine. 2005; 23: 1804-13. PMID: 15734046
16. Kotloff K, Sztein MB, Wassermann SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 2001; 69: 3581-90. PMID: 11349017
17. Tribble DR, Baqar S, Thompson SA. Development of a human vaccine. In Nachamkin I, Szymanski C, Blaser MJ, editors. Campylobacter, 3rd ed. Washington, DC: American Society for Microbiology; 2008. pp. 429-44.
18. Norton EB, Lawson LB, Freytag LC, Clements JD. Characterization of a mutant Escherichia coli heatlabile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol. 2011; 18: 546-51. doi: 10.1128/CVI.00538-10 PMID: 21288994
19. Sjokvist Ottsjo L, Floch CF, Clements J, Holmgren J, Raghavan S. A double-mutant heat-labile toxin from Escherichia coli, LT (R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun. 2013; 81: 1532-40. doi: 10.1128/IAI.01407-12 PMID: 23439305
20. Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol. 2010; 17: 1005-12. doi: 10.1128/CVI.00036-10 PMID: 20427625
21. El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, et al. Saftety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol. 2013; 20: 1764-70. doi: 10.1128/CVI.00464-13 PMID: 24049109
22. Islam A, Raghupathy R, Albert MJ. Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model. Clin Vaccine Immunol. 2010; 17: 1666-71. doi: 10.1128/CVI.00255-10 PMID: 20861330
23. Baqar S, Bourgeois AL, Applebee LA, Mourad AS, Kleinosky MT, Mohran Z, et al. Murine intranasal challenge model for the study of Campylobacter pathogenesis and immunity. Infect Immun. 1996; 64: 4933-9. PMID: 8945529
24. Albert MJ, Udo E, Jose BT, Haridas S, Rotimi VO. Tetracycline resistance is frequent among Campylobacter jejuni isolates from Kuwait. Microb Drug Resist. 2009; 15: 115-20. doi: 10.1089/mdr.2009.0892 PMID: 19432521
25. Blaser MJ, Hopkins JA, Berka RM, Vasil ML, Wang WL. Identification and characterization of Campylobacter jejuni outer membrane proteins. Infect Immun. 1983; 42: 276-284. PMID: 6618667
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227: 680-5. PMID: 5432063
27. Zhang Q, Meitzler JC, Huang S, Morishita T. Sequence polymorphism, predicted secondary structures, and surface-exposed conformational epitopes of Campylobacter major outer membrane protein. Infect Immun. 2000; 68: 5679-89. PMID: 10992471
28. Honda T, Takeda Y, Miwatani T. Isolation of special antibodies which react only with homologous enterotoxins from Vibrio cholerae and enterotoxigenic Escherichia coli. Infect Immun. 1981; 34: 333-6. PMID: 6171516
29. Verweij WR, De Haan L, Holtrop M, Aqsteribbe E, Brands R, van Scharrenburg GJ et al. Mucosal immunoadjuvant activity of the recombinant E. coli eat-labile enterotoxin and its B subunit: induction of systematic IgG and secretory IgA responses in mice by intranasal immunization with influenza surface antigen. Vaccine 1998; 20: 2069-76.
30. Baqar S, Pacheco ND, Rollwagen FM. Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines. Antimicrob Agents Chemother. 1993; 37: 2688-92. PMID: 8109936
31. Baqar S, Applebee LA, Gilliland TC Jr., Lee LH, Porter CK, Guerry P. Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infect Immun. 2008; 76: 3170-5. doi: 10.1128/IAI.00076-08 PMID: 18426878
32. Jertborn M, Nordstrom I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun. 2001; 69: 4125-8. PMID: 11349086
33. Taylor D. Campylobacter infections in developing countries. In Nachamkin I, Blaser M, Tomkins L, editors. Campylobacter jejuni: current status and future trends. Washington, DC: American Society for Microbiology; 1992. pp. 20-30.
34. Taylor DN, Perlman DM, Echeverria PD, Lexomboon U, Blaser MJ. Campylobacter immunity and quantitative excretion rates in Thai children. J Infect Dis. 1993; 168: 754-8. PMID: 8354916
35. Ruiz-Palacios GM, Calva JJ, Pickering LK, Lopez-Vidal Y, Volkow P, Pezzarossi H, et al. Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk. J Pediatr. 1990; 116: 707-13. PMID: 2329419
36. Blaser MJ, Sazie E, Williams LP Jr. The influence of immunity on raw milk-Associated Campylobacter infection. JAMA. 1987; 257: 43-6. PMID: 2431167
37. Black R, Perlman D, Clements M, Levine M, Blaser M. Human volunteer studies with Campylobacter jejuni. In Nachamkin, Blaser M, Tomkins, editors. Campylobacter jejuni: current status and future trends. Washington, DC: American Society for Microbiology; 1992. pp. 207-215.
38. Schroder W, Moser I. Primary structure analysis and adhesion studies on the major outer membrane protein of Campylobacter jejuni. FEMS Microbiol Lett. 1997; 150: 141-7. PMID: 9163918
39. Blaser MJ, Hopkins JA, Vasil ML. Campylobacter jejuni outer membrane proteins are antigenic for humans. Infect Immun. 1984; 43: 986-93. PMID: 6365789
40. Panigrahi P, Losonsky G, DeTolla J, Morris JG Jr. Human immune response to Campylobacter jejuni proteins expressed in vivo. Infect Immun. 1992; 60: 4938-44. PMID: 1399004
41. Huang S, Sahin O, Zhang Q. Infection-induced antibodies against the major outer membrane protein of Campylobacter jejuni may recognize conformational epitopes. FEMS Microbiol Lett. 2007; 272: 137-43 PMID: 17521366
42. PattonWA, Vitale N, Moss J, Vaughan M. Mechanism of cholera toxin action: ADP-ribosylation factors as stimulators of cholera toxin-catalyzed ADP-ribosylation and effectors in intracellular vesicular trafficking events. In Aktories K, Just I, editors. Bacterial protein toxins. Berlin: Springer; 2000. pp.133-152.
43. Leach S, Clements JD, Kaim J, Lundgren A. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS ONE. 2012; 7: e51718. doi: 10.1371/journal.pone.0051718 PMID: 23284753
44. Brereton CF, Sutton CE, Ross PJ, Iwakura Y, Pizza M, Rappuoli R, et al. Escherichia coli heat-Labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol. 2011; 186: 5896-06. doi: 10.4049/jimmunol.1003789 PMID: 21490151
45. Edwards LA, Nistala K, Mills DC, Stephenson HN, Zilbauer M, Wren BW, et al. Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection. PLoS ONE. 2010; 5: e15398. doi: 10.1371/journal.pone.0015398 PMID: 21085698